Short surveyIL-6 signaling in diabetic nephropathy: From pathophysiology to therapeutic perspectives

- Diabetic nephropathy is characterized by the glomerular hypertrophy, overproduction of mesangial matrix and podocyte injury.
- The IL-6 signaling is thought to be involved in the progression of diabetic nephropathy.
- The IL-6 responses mediated via gp130-STAT3 dependent mechanisms trigger the transition from innate to adaptive immune response and regulate immune cell infiltration.
- Imbalanced activation of trans-signaling over classical signaling appears to maintain a pro-inflammatory state.

Diabetic nephropathy (DN) is a leading cause of chronic kidney disease (CKD). Interleukin-6 (IL-6) signaling participates in inflammation responses central to the progression of DN. Current evidence suggests that these IL-6 responses are mediated via gp130-STAT3 dependent mechanisms which, on one hand, trigger globally the transition from innate to adaptive immune response, and on the other hand act locally for tissue remodeling and immune cell infiltration. In diabetic conditions the role of IL-6 is not well elucidated. Both IL-6 classical signaling pathway via receptor IL-6R (IL-6R) and IL-6 trans-signaling pathway via soluble IL-6R (sIL-6R) were shown to participate in the pathogenesis and progression of DN, and IL-6 appears to influence renal cells also in an autocrine manner. To date, evidence is limited. The goal of this review is to provide an overview of our current understanding on the role of IL-6 signaling in DN and to delineate challenges for future research. Putative sequential events related to IL-6 secretion by different cell populations in diabetic conditions are outlined. Further, we discuss potential applications of anti-IL-6 therapy in the context of DN.